Polymorphs are not mythical, chimeric beasts—they are substances with identical chemical compositions but differing crystal structures that also exhibit different physical and chemical properties.

Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation ...

(a) Microscopic image and schematic representation of crystal polymorphs obtained via heteroepitaxial growth (α-phase: green; β-phase: red). Polystyrene particles with a diameter of 860 nm were used ...

The transformation of ritonavir form 1 into a less soluble form 2 is the most notorious example of the risks associated with crystal polymorphism in pharmaceuticals. Since then, significant ...

MADISON, Wis.--(BUSINESS WIRE)--New research by Usona Institute identifies the most favorable environments to achieve consistency and reproducibility of pharmaceutical psilocybin produced at large ...

What is being hailed as a 'cancer treatment breakthrough' comes not from a brand-new experimental drug, but from a 40-year-old medicine used to treat worms. Researchers from Johns Hopkins University ...

Oxides of tin (Sn x O y) are found in many of modern technologies due to their versatile nature. The multivalent oxidation states of tin—Sn 2+ and Sn 4+ —impart tin oxides with electroconductivity, ...

An inexpensive and reliable method for molecular crystal structure predictions (CSPs) has been developed. The new CSP protocol starts from a two-dimensional graph of crystal’s monomer(s) and utilizes ...

Min Son of Hanol IP & Law reports on a ruling by the Supreme Court of Korea that will make it easier to obtain polymorph patents of known chemicals in the country Patenting polymorphs of crystalline ...